Last updated: August 6, 2025
Introduction
The drug identified by NDC 62135-0749 corresponds to Bupropion Hydrochloride Extended-Release (SR) Tablets, 150 mg. This medication, marketed as Wellbutrin SR among other names, is primarily prescribed for major depressive disorder and smoking cessation. As a generic, its market trajectory, pricing dynamics, and competitive landscape are shaped by factors such as patent expiration, therapeutic efficacy, reimbursement policies, and market demand. This analysis offers an in-depth insight into the current market environment, forecasted pricing trends, and strategic considerations for stakeholders.
Market Overview
Therapeutic Landscape
Bupropion SR's therapeutic niche is well-established, with robust usage in depression management and smoking cessation programs. The drug enjoys a broad prescribing base, reinforced by its status as a generic medication, which fosters affordability and wide accessibility. The increased focus on mental health in recent years further amplifies demand, with outpatient prescriptions reaching approximately 25 million annually in the U.S. as of 2022 [1].
Patent and Regulatory Context
Originally patented in the 1980s, Bupropion's patents have long expired, allowing multiple manufacturers to produce generic versions. The specific NDC (National Drug Code) 62135-0749 is associated with a generic formulation that entered the market approximately two years ago, following patent cliffs and biosimilar entries. The FDA approval of multiple generics has intensified price competition and expanded supply.
Market Drivers
- Mental health awareness: Rising recognition of depression and anxiety conditions.
- Smoking cessation initiatives: Coverage expansion for smoking cessation drugs increases utilization.
- COVID-19 pandemic impact: Heightened prevalence of mental health issues has temporarily increased demand.
- Insurance reimbursement policies: Favorable coverage with reduced copayments for generics.
Market Dynamics and Competitive Landscape
Key Competitors
The generic segment for Bupropion SR 150 mg includes several manufacturers such as Mylan (now part of Viatris), Teva, Sun Pharmaceutical, and Lupin. Market share among these is highly fragmented but stable, with a slight concentration among leading producers.
Pricing Patterns
Historically, generic Bupropion SR 150 mg prices have exhibited volatility, driven by supply chain factors, raw material costs, and competitive pressures. The average wholesale acquisition cost (WAC) in 2022 ranged from $0.20 to $0.50 per tablet, with pharmacy retail prices often lower due to discounts and insurance negotiations [2].
Reimbursement and Access
Insurance formularies predominantly favor generics, leading to widespread access. However, formulary restrictions, prior authorizations, and tier placements influence actual patient out-of-pocket costs.
Price Projections (Next 2-3 Years)
Current Price Trends
The current average retail price for NDC 62135-0749, based on recent market data, is approximately $0.25 per tablet. Contracted prices to pharmacies and healthcare systems tend to be lower, often below $0.20.
Projected Price Evolution
-
Short-term (1 Year): Prices are expected to remain relatively stable, with slight fluctuations within a 5-10% range, attributable to stable supply and sustained demand.
-
Medium-term (2-3 Years): As manufacturing capacities expand and new entrants emerge, price compression is anticipated. Competition may drive prices towards $0.15-$0.20 per tablet.
-
Potential Catalysts for Price Changes:
- Entry of additional generic competitors could accelerate price reductions.
- Supply chain disruptions or raw material shortages could temporarily inflate costs.
- Policy changes related to drug pricing and reimbursement could influence net prices.
Influence of Emerging Biosimilars or Alternative Therapies
While biosimilars are not applicable due to the drug's small molecule nature, the emergence of new antidepressants with superior efficacy or fewer side effects could shift market share, impacting demand and prices.
Strategic Considerations for Stakeholders
- Manufacturers: Focus on efficient supply chain management and cost control to maintain profitability amidst declining prices.
- Healthcare Providers: Incorporate cost-effective prescribing practices, favoring generics.
- Payers: Leverage formulary design to promote access to affordable generics, potentially negotiating volume-based discounts.
- Investors: Monitor regulatory and legislative developments that could impact prices and market share.
Regulatory and Legal Factors
Recent legislative efforts aimed at capping drug prices may affect generic prices. Additionally, patent litigations or settlements, though less relevant for this expired patent drug, can influence market dynamics if new patent claims or exclusivities are granted.
Conclusion
The outlook for NDC 62135-0749, a generic Bupropion SR 150 mg, remains steady in terms of demand. Prices are expected to trend slightly downward over the next two years, driven by competition and market maturation. Key to maximizing value will be cost management and strategic positioning in an increasingly competitive environment.
Key Takeaways
- Demand stability: As a well-established therapy, generics like NDC 62135-0749 face sustained demand, especially amidst increasing mental health awareness.
- Price decline trajectory: Prices are projected to decline gradually, potentially reaching below $0.20 per tablet within two years.
- Market competition: Entry of additional players continues to suppress prices, with minimal barriers to entry due to patent expiry.
- Reimbursement dynamics: Payers favor generics, further supporting widespread access and affordability.
- Regulatory risks: Potential policy changes around drug pricing could impact profit margins and market behavior.
FAQs
-
What is the primary therapeutic indication for NDC 62135-0749?
It is primarily prescribed for major depressive disorder and smoking cessation, under the brand name Wellbutrin SR.
-
How does the pricing of this generic compare to the branded version?
The generic version typically costs 60-80% less than the branded counterpart, increasing affordability and accessibility.
-
What factors could disrupt the current market for this drug?
Market disruption could stem from regulatory price controls, new competing drugs, supply chain issues, or changes in prescribing guidelines.
-
Will the price of NDC 62135-0749 decrease further?
Yes, as additional manufacturers enter the market and competition intensifies, further price reductions are anticipated.
-
How can stakeholders optimize their strategies regarding this drug?
Focus on cost management, monitor market entrants, leverage formulary opportunities, and stay abreast of policy changes affecting drug pricing.
References
[1] IQVIA. (2022). Prescription Drug Market Reports.
[2] GoodRx. (2023). Average retail prices for Bupropion SR 150 mg.
